Church, D., et al. · 2018
Depression symptoms decreased by 38% (d=0.9). This trial is also discussed in Church et al. 2022 for finding significant differential expression of six genes (p<0.05) alongside symptom improvement, and its PTSD outcome appears in the Sebastian & Nelms 2017 table (d=2.18).
This is a big deal because gene expression is about as close to hard biology as psychological research gets — genes switching on or off in response to an intervention is not something a person can talk themselves into. Finding measurable differential gene expression alongside symptom improvement is a striking, unusual result, and if it holds up in larger samples, it would give tapping a genuinely molecular account of what might be happening in the body, not just a psychological one.
If a biological signature like this is confirmed in larger studies, picture veterans with PTSD-related depression getting a treatment whose effects can eventually be measured in blood tests, not just self-report questionnaires, giving skeptical clinicians and patients more concrete evidence that something real is happening in the body even when the technique itself is something the veteran administers alone, without a clinician watching each session. That kind of biological grounding could help the approach gain broader acceptance in mainstream medicine.
With six genes already flagged as differentially expressed alongside the depression improvement, the compelling next step is figuring out exactly which genes and pathways are involved — immune and inflammatory genes, HPA-axis-related genes, and genes tied to neuroplasticity are all plausible candidates in PTSD-linked depression. A larger sample with a broader gene panel, paired with cortisol and inflammatory markers, could start to map an actual biological pathway running from tapping session to gene activity to symptom change.
| Design | Randomized trial |
|---|---|
| Participants | 16 people |
| Population | veterans with PTSD |
| Comparison group | treatment as usual |
| Effect size | Cohen's d = 0.9 — on depressive symptoms (SA-45 subscale; figure from the Nelms & Castel secondary table, not stated in the primary paper) |
| Outcome measures | SA-45 |
| Journal | Original publication venue not confirmed (indexed via Nelms & Castel 2016 Table 4; note the meta-analysis was published in 2016, so this citation's 2018 date is likely a later-added/renumbered reference in the secondary source) |
| Year | 2018 |
| Country | United States |
| Language | English |
| Method | EFT / tapping |
| Publication type | Study / trial |
| Verification | Transcribed from a peer-reviewed source; pending independent confirmation |
Church, D., & et al. (2018). Veterans PTSD gene-expression trial — depression outcome (as tabulated in Nelms & Castel 2016). https://doi.org/10.1177/0890117116661154
This record is part of the Tapping Evidence Base — an openly-sourced, fully-referenced directory of the research on EFT/tapping. Explore more studies on Depression · PTSD & Trauma
A ready-made graphic — right-click or long-press to save the image.